• Первичная профилактика рака шейки матки: ресурсно стратифицированное руководство Американского общества клинической онкологии
ru К содержанию

Первичная профилактика рака шейки матки: ресурсно стратифицированное руководство Американского общества клинической онкологии

HEALTH OF WOMAN. 2017.7(123):143–157

Сокращенный вариант. Адаптировано – С.А. Шурпяк

1. Forman D, de Martel C, Lacey CJ, et al: Global burden of human papillomavirus and related diseases. Vaccine 30: F12-F23, 2012 (suppl 5).

2. Castellsague X, Alemany L, Quer M, et al: HPV involvement in head and neck cancers: Comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst 108:djv403, 2016. https://doi.org/10.1093/jnci/djv403; PMid:26823521

3. International Agency for Research on Cancer: GLOBOCAN 2012 cervical cancer: Estimated incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp

4. Chuang LT, Temin S, Berek JS: Management and care of women with invasive cervical cancer: American Society of Clinical Oncology resource-stratified clinical practice guideline summary. J Oncol Pract 12:693-696, 2016. https://doi.org/10.1200/JOP.2016.014290; PMid:27328791

5. Jeronimo J, Castle PE, Temin S, et al: Secondary prevention of cervical cancer: ASCO resource-stratified clinical practice guideline. J Glob Oncol [epub ahead of print on October 28, 2016].

6. de Sanjose S, Serrano B, Castellsague X, et al: Human papillomavirus (HPV) and related cancers in the Global Alliance for Vaccines and Immunization (GAVI) countries: A WHO/ICO HPV Information Centre report. Vaccine 30:D1-D83, vi, 2012 (suppl 4).

7. de Sanjose S, Wheeler CM, Quint WG, et al: Age-specific occurrence of HPV16- and HPV18-related cervical cancer. Cancer Epidemiol Biomarkers Prev 22:1313-1318, 2013. https://doi.org/10.1158/1055-9965.EPI-13-0053; PMid:23632816 PMCid:PMC4306595

8. de Sanjose S, Quint WG, Alemany L, et al: Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol 11:1048-1056, 2010. https://doi.org/10.1016/S1470-2045(10)70230-8

9. Centers for Disease Control and Prevention (CDC): FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Im- munization Practices (ACIP). MMWR Morb Mortal Wkly Rep 59:626-629, 2010. PMid:20508593

10. Markowitz LE, Dunne EF, Saraiya M, et al: Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56:1-24, 2007. PMid:17380109

11. Markowitz LE, Dunne EF, Saraiya M, et al: Human papillomavirus vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 63:1-30, 2014. PMid:25167164

12. Centers for Disease Control and Prevention (CDC): Recommendations on the use of quadrivalent human papillomavirus vaccine in males: Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 60:1705-1708, 2011. PMid:22189893

13. European Medicines Agency: Gardasil 9: EPAR – Summary for thepublic. http: //www.ema.europa.eu/ema/index.jsp? curl5pages/ medicines/ human/medicines/003852/human_med_001863.jsp&mid5WC0b01ac058001d124

14. Centers for Disease Control and Prevention: Provider information: Gardasil 9 vaccine information statements. http:// www. cdc.gov/vaccines/ hcp/vis/vis-statements/hpv-gardasil-9.html

15. Petrosky E, Bocchini JA, Jr., Hariri S, et al: Use of 9-valent human papillomavirus (HPV) vaccine: Updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 64:300-304, 2015. PMid:25811679

16. Wheeler CM, Castellsague м X, Garland SM, et al: Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13:100-110, 2012. https://doi.org/10.1016/S1470-2045(11)70287-X

17. Schiller JT, Castellsague м X, Garland SM: A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30:F123-F138, 2012 (suppl 5).

18. Anderson BO, Shyyan R, Eniu A, et al: Breast cancerin limited-resource countries: An overview of the Breast Health Global Initiative 2005 guidelines. Breast J 12:S3-S15, 2006 (suppl 1).

19. Horton S, Gauvreau CL: Cancer in low- and middle-income countries: An economic overview, in Gelband H, Jha P, Sankaranarayanan R, et al (eds): Cancer Disease Control Priorities (ed 3). Washington, DC, International Bank for Reconstruction and Development/World Bank, 2015. https://doi.org/10.1596/978-1-4648-0349-9_ch16

20. ADAPTE Collaboration: The ADAPTE process: Guidelineadaptation—Areso urcetoolkit(version2.0).http://www.g-i- n.net/document-store/working-groups-documents/adaptation/adapte-resource-toolkit-guideline-adaptation-2-0.pdf

21. Brouwers MC, Kho ME, Browman GP, et al: AGREEII:Advancing guideline development, reporting and evaluation in health care. CMAJ 182:E839-E842, 2010. https://doi.org/10.1503/cmaj.090449; PMid:20603348 PMCid:PMC3001530

22. Shea BJ, Grimshaw JM, Wells GA, et al: Development of AMSTAR: A measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 7:10, 2007. https://doi.org/10.1186/1471-2288-7-10; PMid:17302989 PMCid:PMC1810543

23. Shiffman RN, Michel G, Rosenfeld RM, et al: Building better guidelines with BRIDGE-Wiz: Development and evaluation of a software assistant to promote clarity, transparency, and implementability. J Am Med Inform Assoc 19: 94-101, 2012. https://doi.org/10.1136/amiajnl-2011-000172; PMid:21846779 PMCid:PMC3240753

24. World Health Organization: Meeting of the strategic advisory group of experts on immunization, April 2014: Con- clusions and recommendations. Wkly Epidemiol Rec 89:221-236, 2014. PMid:24864348

25. Couto E, Sжterdal I, Juvet LK, et al: HPV catch-up vaccination of young women: A systematic review and meta- analysis. BMC Public Health 14:867, 2014. https://doi.org/10.1186/1471-2458-14-867; PMid:25149765 PMCid:PMC4159543

26. Public Health Agency of Canada National Advisory Committee on Immunization: Update on the recommended human papillomavirus (HPV) vaccine immunization schedule. https://www.canada.ca/en/public-health/services/publica- tions/healthy-living/update-recommended-human-papillomavirus-vaccine-immunization-schedule.html

27. Gross G, Becker N, Brockmeyer NH, et al: Vaccination against HPV-associated neoplasias: Recommen- dations from the current S3 guideline of the HPV management forum of the Paul-Ehrlich Society—AWMF guidelines, Registry No. 082-002 (short version), valid until Dec. 31st, 2018. Geburtshilfe Frauenheilkd 74: 233-241, 2014. https://doi.org/10.1055/s-0033-1360170

28. Australian Government Department of Health: The Australian Immunisation Handbook (ed 10): 4.6 Human papillomavirus. http: //www. immunise. health. gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home- ~handbook10part4~handbook10-4-6#4-6-7

29. Ben Hadj Yahia MB, Jouin-Bortolotti A, Dervaux B: Extending the human papillomavirus vaccination programme to include males in high-income countries: A systematic review of the cost-effectiveness studies. Clin Drug Investig 35: 471-485, 2015. https://doi.org/10.1007/s40261-015-0308-4; PMid:26187455

30. Fesenfeld M, Hutubessy R, Jit M: Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: A systematic review. Vaccine 31:3786-3804, 2013. ? https://doi.org/10.1016/j.vaccine.2013.06.060; PMid:23830973

31. Armstrong EP: Prophylaxis of cervical cancer and related cervical disease: A review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm 16:217-230, 2010. ? https://doi.org/10.18553/jmcp.2010.16.3.217; PMid:20331326

32. Evidence based recommendations on human papillomavirus (HPV) vaccines schedules: Background paper for SAGE discussions. http: //www. who. int/ immunization/ sage/meetings/ 2014/april/1_HPV_Evidence_based_recommendations-WHO_with_ Appendices2_3.pdf?ua51

33. Centers for Disease Control and Prevention: CDC recommends only two HPV shots for younger adolescents. www. cancerview. ca/ Treatment And Support/GRCMain/GRCSAGE/GRCSAGESearch/

34. World Health Organization: Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec 89:465-491, 2014. PMid:25346960

35. Centers for Disease Control and Prevention (CDC): FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 59:630-632, 2010. PMid:20508594

36. US National Library of Medicine: National Information Center on Health Services Research and Health Care Technology (NICHSR). https: //www. nlm.nih.gov/nichsr/hta101/ta10109.html

37. Sankaranarayanan R, Prabhu PR, Pawlita M, et al: Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: A multicentre prospective cohort study. Lancet Oncol 17:67-77, 2016. https://doi.org/10.1016/S1470-2045(15)00414-3

38. Dobson SR, McNeil S, Dionne M, et al: Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs3 doses in young women: A randomized clinical trial. JAMA 309:1793-1802, 2013. https://doi.org/10.1001/jama.2013.1625; PMid:23632723

39. Krajden M, Cook D, Yu A, et al: Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. Clin Vaccine Immunol 18:418-423, 2011. https://doi.org/10.1128/CVI.00489-10; PMid:21248158 PMCid:PMC3067374

40. Sankaranarayanan R: 2 vs 3 doses HPV vaccine schedule: Low- and middle-income countries. Presented at the Eurogin 2013 International Multidisciplinary Congress, Florence, Italy, November 3-6, 2013.

41. Institut National deSante мPubliqueduQue мbec: La vaccination despre м- adolescents contre les virusdu papillome humain (VPH) au Que мbec: Deux ou trois doses? http://www. inspq.qc.ca/pdf/publications/1683_VaccinPreA- doVPHQc_2ou3Doses.pdf

42. Romanowski B, Schwarz TF, Ferguson LM, et al: Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: Results from a randomized study. Hum Vaccin Immunother 10:1155-1165, 2014. https://doi.org/10.4161/hv.28022; PMid:24576907 PMCid:PMC4896558

43. Romanowski B, Schwarz TF, Ferguson LM, et al: Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: Results from a randomized study. Hum Vaccin 7:1374-1386, 2011. https://doi.org/10.4161/hv.7.12.18322; PMid:22048171 PMCid:PMC3338934

44. GlaxoSmithKline: Evaluation of the safety and immunogenicity of GlaxoSmithKline Biologicals’ HPV vaccine 580299 when administered in healthy females aged 9 – 25 years using an alternative schedule and an alternative dosing as compared to the standard schedule and dosing. http://gsk-clinical study register. com/ files2/ebe3f40a-ef27-469c- 8874-35053b5a80d7

45. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP): Assessment report EMA/ 789820/2013: Cervarix. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/ human/ 000721/WC500160885.pdf

46. Esposito S, Birlutiu V, Jarcuska P, et al: Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: Results from a randomized study. Pediatr Infect Dis J 30:e49-e55, 2011. https://doi.org/10.1097/INF.0b013e318206c26e; PMid:21273939

47. Sankaranarayanan R: Evaluation of fewer than three doses of HPV vaccination in India. Presented at the WHO Consultation Meeting, Geneva, Switzerland, 2013.

48. Lazcano-Ponce E, Stanley M, Mu~noz N, et al: Overcoming barriers to HPV vaccination: Non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine 32:725-732, 2014. https://doi.org/10.1016/j.vaccine.2013.11.059; PMid:24355090

49. Puthanakit T, Huang LM, Chiu CH, et al: Randomized open trial comparing 2-dose regimens of the human pap- illomavirus 16/18 AS04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years. J Infect Dis 214:525-536, 2016 https://doi.org/10.1093/infdis/jiw036; PMid:26908726 PMCid:PMC4957434

50. Garland SM, Stanley M, Brotherton J, et al: IPVS policy statement on safety of HPV vaccines. Papillomavirus Res 2: 9-10, 2016. https://doi.org/10.1016/j.pvr.2015.11.001; PMid:29074192

51. Husereau D, Drummond M, Petrou S, et al: Consolidated Health Economic Reporting Standards (CHEERS): Ex- planation and elaboration—A report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 16:231-250, 2013. https://doi.org/10.1016/j.jval.2013.02.002; PMid:23538175

52. BrissonM, BenardE, DroletM: Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: A systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Pub Health 1: e8-e17, 2016. https://doi.org/10.1016/S2468-2667(16)30001-9

53. Drolet M, Benard E, Boily MC, et al: Population-level impact and herd effects following human papillomavirus vaccination programmes: A systematic review and meta-analysis. Lancet Infect Dis 15:565-580, 2015. https://doi.org/10.1016/S1473-3099(14)71073-4

54. Vichnin M, Bonanni P, Klein NP, et al: An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015. Pediatr Infect Dis J 34:983-991, 2015. https://doi.org/10.1097/INF.0000000000000793; PMid:26107345

55. Garland SM, Ault KA, Gall SA, et al: Pregnancy and infantoutcomesin the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: A combined analysis of five randomized controlled trials. Obstet Gynecol 114:1179-1188, 2009. https://doi.org/10.1097/AOG.0b013e3181c2ca21; PMid:19935017

56. Brotherton JM: Safety of the quadrivalent human papillomavirus vaccine. BMJ 347:f5631, 2013. https://doi.org/10.1136/bmj.f5631; PMid:24108153

57. Arnheim-Dahlstrо L, Pasternak B, Svanstrо m H, et al: Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: Cohort study. BMJ 347:f5906, 2013.

58. Global Advisory Committee on Vaccine Safety, 2-3 December 2015. Wkly Epidemiol Rec 91:21-31, 2016. PMid:26829825

59. Massad LS, Einstein MH, Huh WK, et al: 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 121:829-846, 2013. https://doi.org/10.1097/AOG.0b013e3182883a34; PMid:23635684

60. World Health Organization: WHO Guidelines for Screeningand Treatment of Precancerous Lesions for Cervical Cancer Prevention: WHO Guidelines Approved by the Guidelines Review Committee. Geneva, Switzerland, World Health Organization, 2013.

61. Hildesheim A, Gonzalez P, Kreimer AR, et al: Impact of human papillomavirus (HPV)16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. Am J Obstet Gynecol 215:212.e1-212.e15, 2016. https://doi.org/10.1016/j.ajog.2016.02.021; PMid:26892991 PMCid:PMC4967374

62. Hildesheim A, Wacholder S, Catteau G, et al: Efficacy of the HPV-16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 32:5087-5097, 2014. https://doi.org/10.1016/j.vaccine.2014.06.038; PMid:25018097 PMCid:PMC4166498

63. Kang WD, Choi HS, Kim SM: Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision pro- cedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? Gynecol Oncol 130:264-268, 2013. https://doi.org/10.1016/j.ygyno.2013.04.050; PMid:23623831

64. Joura EA, Garland SM, Paavonen J, et al: Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: Retrospective pooled analysis of trial data. BMJ 344:e1401, 2012. https://doi.org/10.1136/bmj.e1401; PMid:22454089 PMCid:PMC3314184

65. European Medicines Agency: HPV vaccines: EMA confirms еvidence does not support that they cause CRPS or POTS.

66. http: //www. ema. europa. eu/ ema/index.jsp?curl5pages/medicines/human/referrals/Human_papillomavirus_vaccines/human_referral_ prac_000053.jsp&mid5WC0b01ac05805c516f

67. Centersfor Disease Control and Prevention, Foodand Drug Administration:Vaccine Adverse Event Reporting System (VAERS). https://vaers.hhs.gov/index

68. Meites E, Kempe A, and Markowitz LE: Use of a 2-dose schedule for human papillomavirus vaccination– updated rec- ommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 65:1405-1408, 2016. https://doi.org/10.15585/mmwr.mm6549a5; PMid:27977643

69. Garland SM, Subasinghe AK, Jayasinghe YL, et al: HPV vaccination for victims of childhood sexualabuse. Lancet 386: 1919-1920, 2015 https://doi.org/10.1016/S0140-6736(15)00757-6

70. Bailey HH, Chuang LT, duPont NC, et al: American Society of Clinical Oncology Statement: Human papillomavirus vaccination for cancer prevention. J Clin Oncol 34:1803-1812, 2016. https://doi.org/10.1200/JCO.2016.67.2014; PMid:27069078

71. Dorell C, Yankey D, Kennedy A, et al: Factors that influence parental vaccination decisions for adolescents, 13to17 years old: National Immunization Survey-Teen, 2010. Clin Pediatr (Phila) 52: 162-170, 2013. https://doi.org/10.1177/0009922812468208; PMid:23221308

72. Gerend MA, Madkins K, Phillips G II, et al: Predictors of human papillomavirus vaccination among young men who have sex with men. Sex Transm Dis 43:185-191, 2016. https://doi.org/10.1097/OLQ.0000000000000408; PMid:26859806 PMCid:PMC4748724

73. Gerend MA, Shepherd MA, Lustria ML, et al: Predictors of provider recommendation for HPV vaccine among young adult men and women: Findings from a cross-sectional survey. Sex Transm Infect 92:104-107, 2016. https://doi.org/10.1136/sextrans-2015-052088; PMid:26297720

74. Rosenthal SL,Weiss TW, Zimet GD, et al: Predictors of HPV vaccine uptake among women aged 19-26:Importance of a physician’s recommendation. Vaccine 29:890-895, 2011. https://doi.org/10.1016/j.vaccine.2009.12.063; PMid:20056186

75. Lehmann CE, Brady RC, Battley RO, et al: Adolescent vaccination strategies: Interventions to increase coverage. Paediatr Drugs 18:273-285, 2016. https://doi.org/10.1007/s40272-016-0177-1; PMid:27146296

76. Bratic JS, Seyferth ER, Bocchini JAJr: Update on barriers to human papillomavirus vaccination and effective strategies to promote vaccine acceptance. Curr Opin Pediatr 28:407-412, 2016. https://doi.org/10.1097/MOP.0000000000000353; PMid:27093354

77. Lee Mortensen G, Adam M, Idtaleb L: Parental attitudes towards male human papillomavirus vaccination: A pan- European cross-sectional survey. BMC Public Health 15:624, 2015. https://doi.org/10.1186/s12889-015-1863-6; PMid:26152138 PMCid:PMC4495645

78. Gavi The Vaccine Alliance: Countries eligible for support. http: //www.gavi.org/support/apply/countries-eligible-for-support Kiatpongsan S,KimJJ:Costsandcost-effectivenessof9-valenthumanpapillomavirus (HPV) vaccinationin two East African countries. PLoS One 9:e106836, 2014.